About this trial
The aim of the study is to develop a non-invasive method for quantifying cerebral glucose metabolism by PET scans in humans. This method will be used in subsequent studies, where the effect of the pancreatic hormone glucagon on cerebral glucose metabolism will be studied.
The golden standard for quantifying cerebral glucose metabolism by PET scans is based on arterial blood sampling, which complicates research setup. This study will investigate if image derived measurements instead of arterial blood samples can be used to quantify cerebral glucose metabolism.
We will compare the calculations of cerebral glucose metabolism based on arterial blood samples and image derived measurements and hopefully these will correlate.
Healthy participants will be included, and each participant will participate in one study day, which includes intravenous administration of radioactively labelled glucose (18-FDG), arterial blood sampling and PET scans.
Eligibility criteria
Qualifiers
Capable of understanding the participant information and signing the consent form
Between 25 and 70 years of age
Body mass index <= 25 kg/m²
Disqualifiers
Enrolment in other research project that might interfere with the study
Diabetes diagnosis
Pregnancy or breastfeeding
Use of medications which, in the opinion of the investigator, may jeopardise participant's safety or compliance with the protocol
Trial design
Treatments tested in this trial
- PET with 18-FDG
Treatment groups
Sponsors and collaborators
Nicolai Jacob Wewer Albrechtsen
Lead sponsor
University of Copenhagen
Sponsor institution
University Hospital Bispebjerg and Frederiksberg
Collaborator